Picard Medical, Inc. (PMI)
XASE:PMI
Want to see PMI full AI Analyst Report?
PMI Stock Chart & Stats
$1.82
--
Market closed
$1.82
--
Day’s Range― - ―
52-Week Range$0.11 - $13.68
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.38M
Market Cap
N/A
Enterprise Value$232.55M
Total Cash (Recent Filing)$121.00K
Total Debt (Recent Filing)$2.57M
Price to Earnings (P/E)―
Beta-1.02
Next Earnings
Sep 21, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding92,349,846
10 Day Avg. Volume2,124,305
30 Day Avg. Volume2,378,935
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)34.04
Price to Sales (P/S)26.11
P/FCF Ratio-8.23
Enterprise Value/Market Cap10.00T>
Enterprise Value/Revenue42.46
Enterprise Value/Gross Profit279.18
Enterprise Value/Ebitda-12.16
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory-approved Market LeadershipRegulatory approval in major jurisdictions plus an installed base of >2,100 implants creates durable barriers to entry, clinician familiarity, and established referral pathways. This entrenched position supports recurring revenue from drivers, rentals and disposables and strengthens long-term commercial adoption.
Pipeline: Emperor Fully Implantable Heart ProgressAdvancement of the Emperor program into first-in-animal work and second-gen testing represents structural product innovation. A successful fully implantable system could materially expand the addressable market, improve patient quality of life, and differentiate Picard versus competitor solutions over the medium term.
Improving Commercial Traction And MarginsSustained revenue growth and rising gross margins indicate improving unit economics and early scale benefits. If commercial execution and margin expansion persist, the company can progressively reduce funding needs and move toward break-even, making revenue growth more durable and strategically meaningful.
Bears Say
Heavy And Persistent Cash BurnVery large negative operating and free cash flows signal ongoing reliance on external capital to sustain operations. Persistent burn increases refinancing frequency and dilution risk, constrains R&D and commercial investment flexibility, and creates structural vulnerability until profitability or significantly lower cash burn is achieved.
Negative Shareholders' Equity And Going-concern RiskA negative equity position and a going-concern qualification materially weaken financial flexibility and raise refinancing and listing risks. This structural balance-sheet weakness increases cost of capital, limits strategic options, and can force dilutive or restrictive financing if operational cash generation does not improve.
Reliance On Dilutive And Restrictive FinancingFrequent equity offerings, warrant exchanges and high-cost convertible deals indicate constrained access to traditional financing and a reliance on dilutive or restrictive capital. This pattern can compress shareholder value, complicate cap table dynamics, and signal persistent funding risk until operations sustainably generate cash.
Picard Medical, Inc. News
PMI FAQ
What was Picard Medical, Inc.’s price range in the past 12 months?
Picard Medical, Inc. lowest stock price was $0.11 and its highest was $13.68 in the past 12 months.
What is Picard Medical, Inc.’s market cap?
Currently, no data Available
When is Picard Medical, Inc.’s upcoming earnings report date?
Picard Medical, Inc.’s upcoming earnings report date is Sep 21, 2026 which is in 112 days.
How were Picard Medical, Inc.’s earnings last quarter?
Picard Medical, Inc. released its earnings results on May 21, 2026. The company reported -$0.1 earnings per share for the quarter, the consensus estimate of -$0.1 by $0.
Is Picard Medical, Inc. overvalued?
According to Wall Street analysts Picard Medical, Inc.’s price is currently Overvalued.
Does Picard Medical, Inc. pay dividends?
Picard Medical, Inc. does not currently pay dividends.
What is Picard Medical, Inc.’s EPS estimate?
Picard Medical, Inc.’s EPS estimate is -0.03.
How many shares outstanding does Picard Medical, Inc. have?
Picard Medical, Inc. has 92,349,846 shares outstanding.
What happened to Picard Medical, Inc.’s price movement after its last earnings report?
Picard Medical, Inc. reported an EPS of -$0.1 in its last earnings report, expectations of -$0.1. Following the earnings report the stock price went down -8.442%.
Which hedge fund is a major shareholder of Picard Medical, Inc.?
Currently, no hedge funds are holding shares in PMI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Picard Medical, Inc.
Picard Medical, Inc., through its subsidiaries, engages in the designing, manufacturing, production, supply, marketing, and sale of medical device products. The company offers SynCardia TAH, an artificial heart for patients that is designed to function as a failed human heart in patients suffering from advanced heart failure. The company operates in the USA, Europe, and internationally. The company was incorporated in 2021 and is based in Tucson, Arizona. Picard Medical, Inc. operates as a subsidiary of Hunniwell Picard I, Llc
PMI Company Deck
PMI Earnings Call
Q4 2026
0:00 / 0:00
PMI Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Aethlon Medical
―
―
Catheter Precision
―
Heart Test Laboratories, Inc.
―
Autonomix Medical, Inc.
―
Ownership Overview
―
Insiders
0.11% Mutual Funds
0.05% Other Institutional Investors
99.79% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---